Despite growth, the Chondrosarcoma Market faces challenges typical of rare cancers. Small patient numbers complicate clinical trial design and limit commercial incentives. Diagnostic delays may occur where awareness and imaging access are limited. Treatment options beyond surgery remain constrained, especially for high‑grade or unresectable tumors. At the same time, opportunities exist in...